COPD oh boy another Me Too from Novartis

[Anonymous]

SO LOOKS LIKE THE CLOWNS ARE COPYING SOMEONE ELSE AS USUAL
Change the Name of the Co. to NORIGINALITY
FDA will probably smack down this uneeded me too

Novartis lung drug has similar efficacy to rival

ZURICH | Thu Jun 30, 2011 4:46am EDT

ZURICH (Reuters) - Swiss drugmaker Novartis AG experimental lung drug NVA237 helps patients with a life threatening respiratory disease in a similar way to a rival drug from Pfizer and Boehringer Ingelheim, a late-stage study showed

NVA237 was licensed to Novartis in 2005 by Vectura and its co-development partner Sosei.

At 0719 GMT, Novartis shares were flat

 

[Anonymous]

DING DONG COPD IS DEAD ...

U.S. FDA approves low dose of Novartis lung drug
Fri Jul 1, 2011 4:25pm EDT

For Novartis to develop such drug, it needed approval for a higher 150 mcg dose of Arcapta Neohaler, which is sold as a a single therapy in Europe under the brand name Onbrez Breezhaler and had revenue of $33 million in 2010.

The 150 microgram dose of Arcapta Neohaler failed to win support from a U.S. advisory panel